The effects of cannabidiol against Methotrexate‐induced lung damage
Basic & Clinical Pharmacology & Toxicology · 2024-05 · 134 (5) · 695-703
DOI: 10.1111/bcpt.13992 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, published online on 2024-02-22. Written by Ozlem Ozmen and 4 co-authors. Institution: Faculty of Veterinary Medicine, Department of Pathology, Burdur Mehmet Akif Ersoy University, Burdur, Turkey. Major MEDLINE topics: Methotrexate, Cannabidiol. Cited 14 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Suleyman Demirel University.
Abstract (original language)
Methotrexate (MTX) is a widely used medication for various cancers, yet its use is associated with adverse effects on organs, notably the lungs. Cannabidiol (CBD), known for its antioxidant and anti‐inflammatory properties, was investigated for its potential protective effects against MTX‐induced lung injury. Thirty‐two female Wistar Albino rats were divided into four groups: control, MTX (single 20 mg/kg intraperitoneal dose), MTX + CBD (single 20 mg/kg MTX with 0.1 ml of 5 mg/kg CBD for 7 days intraperitoneally) and CBD only (for 7 days). Lung tissues were analysed using histopathological, immunohistochemical and PCR methods after the study. Histopathological assessment of the MTX group revealed lung lesions like hyperemia, edema, inflammatory cell infiltration and epithelial cell loss. Immunohistochemical examination showed significant increases in Cas‐3, tumour necrosis factor‐alpha (TNF‐α) and nuclear factor‐kappa B (NF‐κB) expressions. PCR analysis indicated elevated expressions of apoptotic peptidase activating factor 1 (Apaf 1), glucose‐regulated protein 78 (GRP 78), CCAAT‐enhancer‐binding protein homologous protein (CHOP) and cytochrome C (Cyt C), along with reduced B‐cell lymphoma‐2 (BCL 2) expressions in the MTX group, though not statistically significant. Remarkably, CBD treatment reversed these findings. This study highlights CBD's potential in mitigating MTX‐induced lung damage, suggesting its therapeutic promise.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Veterinary Medicine, Department of Pathology, Burdur Mehmet Akif Ersoy University, Burdur, Turkey.
- Faculty of Medicine, Department of Medical Biology, Suleyman Demirel University, Isparta, Turkey.
- Faculty of Medicine, Department of Medical Pharmacology, Suleyman Demirel University, Isparta, Turkey.
ORCID profiles: Ozlem Ozmen, Adem Milletsever, Serife Tasan, Esma Selcuk, Mehtap Savran
Funding
- Suleyman Demirel University
Cite
APA
Ozmen, O., Milletsever, A., Tasan, S., Selcuk, E., & Savran, M. (2024). The effects of cannabidiol against Methotrexate‐induced lung damage. Basic & Clinical Pharmacology & Toxicology, 134(5), 695-703. https://doi.org/10.1111/bcpt.13992
Vancouver
Ozmen O, Milletsever A, Tasan S, Selcuk E, Savran M. The effects of cannabidiol against Methotrexate‐induced lung damage. Basic & Clinical Pharmacology & Toxicology. 2024;134(5):695-703. doi:10.1111/bcpt.13992
BibTeX
@article{Ozmen2024,
author = {Ozmen, Ozlem and Milletsever, Adem and Tasan, Serife and Selcuk, Esma and Savran, Mehtap},
title = {The effects of cannabidiol against Methotrexate‐induced lung damage},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
volume = {134},
number = {5},
pages = {695--703},
doi = {10.1111/bcpt.13992}
}
EUVIMED